Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

161. Outbreak of Adverse Reactions Associated with Contaminated Heparin. Full Text available with Trip Pro

Outbreak of Adverse Reactions Associated with Contaminated Heparin. In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions.Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent with an allergic-type reaction (...) after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants.A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin manufactured by Baxter Healthcare

2008 NEJM

162. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes Full Text available with Trip Pro

Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes The aim of this study was to determine the economic impact of several anticoagulation strategies for moderate- and high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients managed invasively.The ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial (...) demonstrated that bivalirudin monotherapy yields similar rates of ischemic complications and less bleeding than regimens incorporating glycoprotein IIb/IIIa receptor inhibitors (GPI) for moderate- and high-risk NSTE-ACS.In ACUITY, 7,851 U.S. patients were randomized to: 1) heparin (unfractionated or enoxaparin) + GPI; 2) bivalirudin + GPI; or 3) bivalirudin monotherapy. Patients assigned to GPI were also randomized to upstream GPI before catheterization or selective GPI only with percutaneous coronary

2008 EvidenceUpdates Controlled trial quality: uncertain

163. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Full Text available with Trip Pro

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Elderly patients are at high risk from non-ST-segment elevation acute coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated (...) heparin (UFH) in patients with high-risk NSTE ACS.Age was analysed as a continuous and categorical variable (<65, 65-74, and >or=75 years, and <75 and >or=75 years) for descriptive purposes. Logistic regression was used to adjust the outcomes of 30-day death, death or myocardial infarction (MI), and major bleeding for baseline characteristics. Odds ratios compared outcomes by age and by treatment within age groups. Model interaction terms were used to test for statistically different outcomes

2008 EvidenceUpdates Controlled trial quality: uncertain

164. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. (Abstract)

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005.To compare the effects of low-molecular-weight heparins (...) or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke.We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies.Randomised trials comparing

2008 Cochrane

165. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease

Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease BestBets: Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Report By: Andrew Munro - Staff Specialist Search checked by Cain English - Emergency Registrar Institution: Coffs Harbour Base Hospital Date (...) Submitted: 4th September 2007 Date Completed: 8th May 2008 Last Modified: 5th November 2007 Status: Green (complete) Three Part Question In [patients with DVT] is [subcutaneous unfractionated heparin as efficacious as low-molecular-weight heparin] in the [prevention of thrombo-embolic sequelae]? Clinical Scenario An Emergency Department Registrar presented a paper at our journal club showing the efficaciousness and cost effectiveness of home treatment with unfractionated heparin (UFH) in comparison

2008 BestBETS

166. Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. Full Text available with Trip Pro

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating heparin supplies worldwide, is the cause of the severe anaphylactoid reactions that have occurred after intravenous heparin administration in the United States and Germany.Heparin procured from the Food and Drug Administration, consisting of suspect lots of heparin associated (...) with the clinical events as well as control lots of heparin, were screened in a blinded fashion both for the presence of OSCS and for any biologic activity that could potentially link the contaminant to the observed clinical adverse events. In vitro assays for the activation of the contact system and the complement cascade were performed. In addition, the ability of OSCS to recapitulate key clinical manifestations in vivo was tested in swine.The OSCS found in contaminated lots of unfractionated heparin, as well

2008 NEJM

167. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. (Abstract)

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown.We enrolled 4570 patients with stable or unstable angina (with normal levels of troponin T and creatine kinase MB) who were undergoing PCI after pretreatment with a 600-mg dose of clopidogrel at least 2 hours (...) before the procedure; 2289 patients were randomly assigned in a double-blind manner to receive bivalirudin, and 2281 to receive unfractionated heparin. The primary end point was the composite of death, myocardial infarction, urgent target-vessel revascularization due to myocardial ischemia within 30 days after randomization, or major bleeding during the index hospitalization (with a net clinical benefit defined as a reduction in the incidence of the end point). The secondary end point

2008 NEJM Controlled trial quality: predicted high

168. Heparins reduce the number of heart attacks after acute coronary syndromes

Heparins reduce the number of heart attacks after acute coronary syndromes PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Heparins reduce the number of heart attacks after acute coronary syndromes Clinical question How effective are heparins in the treatment of patients with acute coronary syndromes (ACS)? Bottom line Compared to placebo, heparins reduce the number of heart attacks (NNT* 33) but cause more minor bleeding (NNH* 17) after ACS. The risks of mortality, revascularisation, recurrent angina, major bleeding and thrombocytopenia were similar in both groups. *NNT = number needed to treat to benefit one

2008 Cochrane PEARLS

169. Low molecular weight heparin is more effective than vitamin K

Low molecular weight heparin is more effective than vitamin K PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Low molecular weight heparin is more effective than vitamin K antagonists for venous thromboembolism in cancer patients Clinical question How effective and safe are low molecular weight heparin (LMWH) and anticoagulants such as vitamin K antagonists (VKA) for the long term treatment of venous thromboembolism (VTE) in patients with cancer? Bottom line For the long term treatment (up to 6 months) of VTE in patients with cancer, LMWH compared to VKA reduces venous thromboembolic events

2008 Cochrane PEARLS

170. Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer

Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancerCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancerCommentary Article Text Treatment Review

2008 Evidence-Based Nursing

171. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery

Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

172. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity

Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Bramham K, Varrier M, Asgari E, Makanjuola D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the costs and outcomes associated with the use of unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH, Tinzaparin TM ) for anticoagulation in patients on haemodialysis. The authors concluded

2008 NHS Economic Evaluation Database.

173. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. (Abstract)

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery.To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen.Prospective cohort study.Single university hospital.Consecutive patients who had warfarin therapy interrupted before an invasive (...) procedure.Enoxaparin, 1 mg/kg of body weight, twice daily. The last dose was administered the evening before surgery.Blood anti-factor Xa heparin levels measured shortly before surgery.Preoperative anti-Xa heparin levels were obtained in 80 patients at an average of 14 hours after the last dose of enoxaparin was administered. The average anti-Xa heparin level was 0.6 U/mL. The anti-Xa heparin level, measured shortly before surgery, was 0.5 U/mL or greater in 54 (68%) patients and 1.0 U/mL or greater in 13 (16

2007 Annals of Internal Medicine

174. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. (Abstract)

The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Venous thromboembolism prophylaxis with low molecular weight heparin or unfractionated heparin is recommended in acute ischaemic stroke, but which regimen provides optimum treatment is uncertain. We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients (...) with stroke.1762 patients with acute ischaemic stroke who were unable to walk unassisted were randomly assigned within 48 h of symptoms to receive either enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5000 U subcutaneously every 12 h for 10 days (range 6-14). Patients were stratified by National Institutes of Health Stroke Scale (NIHSS) score (severe stroke > or =14, less severe stroke <14). The primary efficacy endpoint was the composite of symptomatic or asymptomatic deep vein

2007 Lancet Controlled trial quality: predicted high

175. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials Full Text available with Trip Pro

Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials Dumaine R, Borentain M (...) , Bertel O, Bode C, Gallo R, White H D, Collet J P, Steinhubl S R, Montalescot G CRD summary This review concluded that the use of low molecular weight heparins during percutaneous coronary intervention reduces the risk of major bleeding compared with unfractionated heparin, and is as efficacious. The findings should be treated with some caution, owing to a number of methodological weaknesses in the conduct of the review and clinical variation between the included studies. Authors' objectives

2007 DARE.

176. Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review

Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

177. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials

Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

178. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes

Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

179. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis

Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

180. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis

No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.